1. DNA‐Based Synthetic Growth Factor Surrogates with Fine‐Tuned Agonism**
- Author
-
Masataka Yanagawa, Momoko Akiyama, Mitsuhiro Abe, Yasushi Sako, Michio Hiroshima, Shinsuke Sando, and Ryosuke Ueki
- Subjects
Agonist ,medicine.drug_class ,Aptamer ,medicine.medical_treatment ,Computational biology ,Ligands ,Partial agonist ,Catalysis ,chemistry.chemical_compound ,Cell Movement ,Human Umbilical Vein Endothelial Cells ,medicine ,Humans ,Agonism ,Receptors, Cytokine ,Receptor ,Hepatocyte Growth Factor ,Chemistry ,Growth factor ,General Medicine ,General Chemistry ,Aptamers, Nucleotide ,Proto-Oncogene Proteins c-met ,Microscopy, Fluorescence ,A549 Cells ,Intercellular Signaling Peptides and Proteins ,Signal transduction ,Dimerization ,DNA ,Protein Binding ,Signal Transduction - Abstract
Designing synthetic surrogates of functional proteins is an important, albeit challenging, task in the field of chemistry. A strategy toward the design of synthetic agonists for growth factor or cytokine receptors that elicit a desired signal activity has been in high demand, as such ligands hold great promise as safer and more effective therapeutics. In the present study, we used a DNA aptamer as a building block and described the strategy-guided design of a synthetic receptor agonist with fine-tuned agonism. The developed synthetic partial agonist can regulate therapeutically relevant cellular activities by eliciting fine-tuned receptor signaling.
- Published
- 2021
- Full Text
- View/download PDF